Roche says that its tender offer for stock in Genentech it did not already own has been completed, giving it control of over 96% of the shares in US biotechnology giant.

The Basel-based firm noted that together with the 55.7% stake it already held, Roche currently holds a total of approximately 982.9 million or 93.2% of Genentech shares outstanding. A further 3% are “guaranteed to be delivered within the next three business days” which will represent a 96.2% holding.

The remaining holders of Genentech shares will receive $95 a share like everybody else, effectively sealing the $46.8 billion buy-out. Genentech will now become a wholly-owned subsidiary of Roche and its stock will be delisted from the New York Stock Exchange.